A randomized prospective trial of low-dose OKT3 induction therapy to prevent rejection and minimize side effects in recipients of kidney transplants

Transplantation

Volumn 69, Issue 11, 2000, Pages 2374-2381

  Flechner, Stuart M ^a   Goldfarb, David A ^a   Fairchild, Robert ^a   Modlin, Charles S ^a   Fisher, Rosemaree ^a   Mastroianni, Barbara ^a   Boparai, Navdeep ^a   O'Malley, Kiaran J ^a   Cook, Daniel J ^a   Novick, Andrew C ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; INTERLEUKIN 6; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; ORTHOCLONE; STEROID; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

EID: 0034660564     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200006150-00027     Document Type: Article

References (46)

1. Shield CF, Edwards EB, Davies DB, Dailey OP. Antilymphocyte induction therapy in cadaver renal transplant: a retrospective, multicenter, UNOS study. Transplantation 1997; 63: 1257.
2. Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a metaanalysis. J Am Soc Nephrol 1997; 8: 1771.
3. Opelz G. Collaborative Transplant Study: efficacy of rejection prophylaxis with OKT3 in renal transplantation. Transplantation 1995; 60: 1220.
4. Cecka JM, Cho YW, Terasaki PI. Analyses of the UNOS scientific renal transplant registry at three years: early events affecting transplant success. Transplantation 1992; 53: 59.
5. Pratschke J, Wilhelm MJ, Kusaka M, et al. Brain death and its influence on donor organ quality and outcome after transplantation. Transplantation 1999; 67: 434.
6. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplantation. N Engl J Med 1990; 323: 1723.
7. Steinmuller D, Hayes JM, Novick AC, et al. Comparison of OKT3 with ALG for prophylaxis for patients with acute renal failure after cadaver renal transplantation. Transplantation 1991; 52: 67.
8. Frey DJ, Matas AJ, Gillingham KJ, et al. Sequential therapy-A prospective randomized trial of MALG vs OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients. Transplantation 1992; 54: 50.
9. Hanto DW, Jendrisak MD, So SK, et al. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Transplantation 1994; 57: 377.
10. Abouna GM, Al-Abdullah I, Kelly-Sullivan D, et al. Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation 1995; 59: 1564.
11. Bock HA, Gallati H, Zurcher RM, et al. A randomized prospective trial of prophylactic immunosuppression with ATG-Fresenius vs. OKT3 after renal transplantation. Transplantation 1995; 59: 830.
12. Brennan DC, Flavin K, Lowell JA, et al. A randomized double blinded comparison of thymoglobulin vs. Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011.
13. Abramowicz D, Goldman M, DePauw L, et al. Long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation: a single center prospective randomized study. Transplantation 1992; 54: 433.
14. Norman DJ, Kahana L, Stuart FP, et al. A randomized trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44.
15. Shield CF, Jacobs J, Wyant S, Das A. A cost-effective analysis of OKT3 induction therapy in cadaveric kidney transplantation. Am J Kidney Dis 1996; 27: 855.
16. Abramowicz, D Norman, DJ Vereerstraeten, P, et al. OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term graft survival. Kidney Int 1996; 49: 768.
17. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-γ. N Engl J Med 1989; 320: 1420.
18. Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606.
19. Kreis H. Adverse events associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplant 1993; 7: 431.
20. Jaffers GJ, Fuller TC, Cosimi AB, et al. Monoclonal anti-body therapy: anti-idiotypic and non anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 1986; 41: 572.
21. Legendre C, Kreis H, Bach JF, Chatenoud L. Prediction of successful allograft rejection retreatment with OKT3. Transplantation 1992; 53: 87.
22. Carey G, Lisi PJ, Schroeder TJ. The incidence of antibody formation to OKT3 consequent to its use in organ transplantation. Transplantation 1995; 60: 151.
23. Flechner SM, Avery RK, Fisher R, et al. A Randomized prospective controlled trial or oral acyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in high risk kidney transplant recipients. Transplantation 1998; 66: 1682.
24. Wilcoxon F. Individual comparisons by ranking methods. Biometrics Bull 1955; 1: 80.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457.
26. Cox DR. Regression models and life tables. J R Stat Soc Series B, 1972; 34: 187.
27. Norman DJ, Barry JM, Bennet WM, et al. OKT3 induction immunosuppression in renal transplantation: a comparative study of high vs. low doses. Transplant Proc 1991; 23: 1052.
28. Alloway R, Kotb M, Hathaway D, et al. A randomized double blind study of standard vs low dose OKT3 induction therapy in renal allograft recipients. Am J Kidney Dis 1993; 22: 36.
29. Hesse CJ, Heyse P, Stolk B, et al. Immune monitoring of heart transplant patients receiving either one or two cycles of OKT3 prophylaxis. Clin Transplant 1991; 5: 446.
30. Broeders N, Wissing KM, Crusiaux A, et al. Mycophenolate mofetil together with cyclosporin A prevents anti-OKT3 anti-body response in kidney transplant recipients. J Am Soc Nephrol 1998; 9: 1521.
31. US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
32. Henry ML, Elkhammas MD, Bumgardner GL, et al. A prospective randomized trial of Neoral and Cellcept with and without OKT3 induction. Proc Am Soc Transplant Surgeons 1998; 24.
33. Flechner SM, Modlin CS, Serrano DP, et al. Determinants of chronic renal allograft rejection in cyclosporine treated patients. Transplantation 1996; 62: 1235.
34. Touissant C, De Pauw L, Vereerstaeten P, et al. Possible nephrotoxicity of the prophylactic use of OKT3 monoclonal antibody after cadaveric renal transplantation. Transplantation 189; 48:524.
35. Abramowicz D, Pradier O, Marchant A, et al. Induction of thromboses within renal grafts by high dose prophylactic OKT3. Lancet 1992; 339.
36. Allison AC. The immunosuppressive actions of mycophenolic acid. Immunol Rev 1993; 136: 1.
37. Kimball JA, Pescovitz M, Book BK, Norman DJ. Reduced human IgG anti-Atgam antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 1995; 60: 1379.
38. Gaston RS, Deirhoi MH, Patterson T, et al. OKT3 first dose reaction: association with T cell subsets and cytokine release. Kidney Int 1991; 39: 141.
39. Chatenoud L, Legendre C, Ferran C, et al. Corticosteroid inhibition of OKT3 induced cytokine related syndrome-dosage and kinetics prerequisites. Transplantation 1991; 51: 334.
40. Pescovitz MD, Milgrom ML, Leapman SB, Filo RS. Corticosteroid inhibition of the OKT3 induced febrile and nephrotoxic responses during treatment of renal allograft rejection. Clin Transplant 1993; 7: 529.
41. Waage A, Bakke O. Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes. Immunology 1987; 63: 299.
42. Kern JA, Lamb RJ, Reed JC, et al. Dexamethasone inhibition of interleukin 1 production by human monocytes: post transcriptional mechanisms. J Clin Invest 1988; 821: 237.
43. Bemelman FJ, Buysmann S, Surachno J, et al. Pretreatment with divided doses of steroids strongly decreases side effects of OKT3. Kidney Int 1994; 46: 1674.
44. Bemelman FJ, Buysmann S, Wilmink JM, et al. Effects of divided doses of steroids on side effects, cytokines, and activation of complement and granulocytes, coagulation and fibrinolysis after OKT3. Transplant Proc 1994; 26: 3096.
45. Nashan B, Moore R, Amlot P, et al., for the CHIB 201 International Study Group. Randomized trial of basiliximab vs. placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1193.
46. Vincenti F, Kirkman R, Light S, et al. For the daclizumab triple therapy study group: Interleukin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.